Organisation paid for research Program year 2025 Source: CMS Open Payments

Susan H Weinkle MD

Neither a doctor nor a teaching hospital

Research payments

$642,810

98 payments

Through program year 2025, Susan H Weinkle MD is reported as receiving $642,810 in research payments, across 98 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$120,129	13
2024	Research	$51,777	7
2023	Research	$6,747	1
2022	Research	$117,167	25
2021	Research	$73,621	14
2020	Research	$177,939	25
2019	Research	$95,428	13

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $373,281 56 payments
AbbVie, Inc. $269,529 42 payments

Studies the money was for Research payments · program years 2019–2025

Ph 3 Pivotal LCL and GL+ LCL - US/EU $124,703 17 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $98,337 13 payments
Voluma Temple US $79,346 12 payments
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence $73,536 13 payments
Voluma Temple US $63,579 10 payments
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $49,524 7 payments
Ph 3 Pivotal LCL and GL LCL - USEU $45,904 6 payments
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $36,618 3 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $23,183 2 payments
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $12,170 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.